ID   GTL-16
AC   CVCL_7668
SY   GTL 16; GTL16
DR   EFO; EFO_0006578
DR   ArrayExpress; E-MTAB-2706
DR   ChEMBL-Cells; CHEMBL3308698
DR   ChEMBL-Targets; CHEMBL612708
DR   Cosmic; 755306
DR   Cosmic; 755613
DR   Cosmic; 887246
DR   Cosmic; 1945868
DR   Cosmic; 2069777
DR   Cosmic; 2484973
DR   Cosmic; 2807624
DR   GEO; GSM685812
DR   GEO; GSM686033
DR   GEO; GSM686034
DR   GEO; GSM843505
DR   GEO; GSM1178098
DR   GEO; GSM1178099
DR   GEO; GSM1374485
DR   GEO; GSM1374486
DR   PharmacoDB; GTL16_418_2019
DR   Progenetix; CVCL_7668
DR   Wikidata; Q54871835
RX   PubMed=1486568;
RX   PubMed=1674365;
RX   PubMed=2541345;
RX   PubMed=22745804;
RX   PubMed=24807215;
RX   PubMed=25485619;
CC   Population: Japanese.
CC   Characteristics: MET is amplified and overexpressed in this cell line.
CC   Sequence variation: Heterozygous for TP53 p.Arg110Cys (c.328C>T) (ClinVar=VCV000142206) (from parent cell line).
CC   Omics: Deep exome analysis.
CC   Omics: Deep RNAseq analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis.
CC   Derived from metastatic site: Liver.
DI   NCIt; C4004; Gastric adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens
HI   CVCL_0434 ! MKN45
SX   Female
AG   62Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 29-10-20; Version: 23
RX   PubMed=1486568; DOI=10.1016/0165-4608(92)90350-H;
RA   Rege-Cambrin G., Scaravaglio P., Carozzi F., Giordano S., Ponzetto C.,
RA   Comoglio P.M., Saglio G.;
RT   "Karyotypic analysis of gastric carcinoma cell lines carrying an
RT   amplified c-met oncogene.";
RL   Cancer Genet. Cytogenet. 64:170-173(1992).
RX   PubMed=1674365;
RA   Ponzetto C., Giordano S., Peverali F., Della Valle G., Abate M.L.,
RA   Vaula G., Comoglio P.M.;
RT   "c-met is amplified but not mutated in a cell line with an activated
RT   met tyrosine kinase.";
RL   Oncogene 6:553-559(1991).
RX   PubMed=2541345; DOI=10.1038/339155a0;
RA   Giordano S., Ponzetto C., Di Renzo M.F., Cooper C.S., Comoglio P.M.;
RT   "Tyrosine kinase receptor indistinguishable from the c-met protein.";
RL   Nature 339:155-156(1989).
RX   PubMed=22745804; DOI=10.1371/journal.pone.0039653;
RA   Lee N.V., Lira M.E., Pavlicek A., Ye J., Buckman D., Bagrodia S.,
RA   Srinivasa S.P., Zhao Y., Aparicio S., Rejto P.A., Christensen J.G.,
RA   Ching K.A.;
RT   "A novel SND1-BRAF fusion confers resistance to c-Met inhibitor
RT   PF-04217903 in GTL16 cells through MAPK activation.";
RL   PLoS ONE 7:E39653-E39653(2012).
RX   PubMed=24807215; DOI=10.1038/ncomms4830;
RA   Liu J., McCleland M., Stawiski E.W., Gnad F., Mayba O., Haverty P.M.,
RA   Durinck S., Chen Y.-J., Klijn C., Jhunjhunwala S., Lawrence M., Liu H.,
RA   Wan Y., Chopra V., Yaylaoglu M.B., Yuan W., Ha C., Gilbert H.N.,
RA   Reeder J., Pau G., Stinson J., Stern H.M., Manning G., Wu T.D.,
RA   Neve R.M., de Sauvage F.J., Modrusan Z., Seshagiri S., Firestein R.,
RA   Zhang Z.;
RT   "Integrated exome and transcriptome sequencing reveals ZAK isoform
RT   usage in gastric cancer.";
RL   Nat. Commun. 5:3830-3830(2014).
RX   PubMed=25485619; DOI=10.1038/nbt.3080;
RA   Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z., Liu H.,
RA   Degenhardt J., Mayba O., Gnad F., Liu J., Pau G., Reeder J., Cao Y.,
RA   Mukhyala K., Selvaraj S.K., Yu M., Zynda G.J., Brauer M.J., Wu T.D.,
RA   Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D.,
RA   Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S.,
RA   Zhang Z.;
RT   "A comprehensive transcriptional portrait of human cancer cell
RT   lines.";
RL   Nat. Biotechnol. 33:306-312(2015).